Literature DB >> 11120946

Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.

K L Credito1, G Lin, G A Pankuch, S Bajaksouzian, M R Jacobs, P C Appelbaum.   

Abstract

The activity of the ketolide ABT-773 against Haemophilus and Moraxella was compared to those of 11 other agents. Against 210 Haemophilus influenzae strains (39.0% beta-lactamase positive), microbroth dilution tests showed that azithromycin and ABT-773 had the lowest MICs (0.5 to 4.0 and 1.0 to 8.0 microg/ml, respectively), followed by clarithromycin and roxithromycin (4.0 to >32.0 microg/ml). Of the beta-lactams, ceftriaxone had the lowest MICs (</=0.004 to 0.016 microg/ml), followed by cefixime and cefpodoxime (0.008 to 0.125 and </=0.125 to 0.25 microg/ml, respectively), amoxicillin-clavulanate (0.125 to 4.0 microg/ml), and cefuroxime (0. 25 to 8.0 microg/ml). Amoxicillin was only active against beta-lactamase-negative strains, and cefprozil had the highest MICs of all oral cephalosporins tested (0.5 to >32.0 microg/ml). Against 50 Moraxella catarrhalis strains, all of the compounds except amoxicillin and cefprozil were active. Time-kill studies against 10 H. influenzae strains showed that ABT-773, at two times the MIC, was bactericidal against 9 of 10 strains, with 99% killing of all strains at the MIC after 24 h; at 12 h, ABT-773 gave 90% killing of all strains at two times the MIC. At 3 and 6 h, killing by ABT-773 was slower, with 99.9% killing of four strains at two times the MIC after 6 h. Similar results were found for azithromycin, with slightly slower killing by erythromycin, clarithromycin, and roxithromycin, especially at earlier times. beta-Lactams were bactericidal against 8 to 10 strains at two times the MIC after 24 h, with slower killing at earlier time periods. Most compounds gave good killing of five M. catarrhalis strains, with beta-lactams killing more rapidly than other drugs. ABT-773 and azithromycin gave the longest postantibiotic effects (PAEs) of the ketolide-macrolide-azalide group tested (4.4 to >8.0 h), followed by clarithromycin, erythromycin, and roxithromycin. beta-Lactam PAEs were similar and shorter than those of the ketolide-macrolide-azalide group for all strains tested.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120946      PMCID: PMC90241          DOI: 10.1128/AAC.45.1.67-72.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases.

Authors:  G D Fang; M Fine; J Orloff; D Arisumi; V L Yu; W Kapoor; J T Grayston; S P Wang; R Kohler; R R Muder
Journal:  Medicine (Baltimore)       Date:  1990-09       Impact factor: 1.889

Review 2.  Haemophilus influenzae: antibiotic susceptibility.

Authors:  C A Needham
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  T A Davies; L M Kelly; D B Hoellman; L M Ednie; C L Clark; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae.

Authors:  F W Goldstein; M F Emirian; A Coutrot; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes.

Authors:  J P Maskell; A M Sefton; J D Williams
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.

Authors:  R Dagan; C E Johnson; S McLinn; N Abughali; J Feris; E Leibovitz; D J Burch; M R Jacobs
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

8.  Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.

Authors:  R Dagan; E Leibovitz; D M Fliss; A Leiberman; M R Jacobs; W Craig; P Yagupsky
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

9.  In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.

Authors:  B Olsson-Liljequist; B M Hoffman
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

10.  The development of macrolides: clarithromycin in perspective.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

View more
  11 in total

1.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.

Authors:  Klaudia Kosowska; Kim Credito; Glenn A Pankuch; Dianne Hoellman; Gengrong Lin; Catherine Clark; Bonifacio Dewasse; Pamela McGhee; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 4.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  M M Neuhauser; J L Prause; L H Danziger; S L Pendland
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 6.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.

Authors:  Michael E Pichichero; Gary V Doern; Joseph L Kuti; David P Nicolau
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 8.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Authors:  Glenn A Pankuch; Linda M Kelly; Gengrong Lin; Andre Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Activities of HMR 3787 and RU 64399 compared with those of four other agents against Haemophilus influenzae and Haemophilus parainfluenzae.

Authors:  Bülent Bozdogan; Catherine Clark; Andre Bryskier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.